Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Aw you so smart you timed the exit and then got back in after dust bunny came out your ass. Man I wish I could be like you with the timing!
Fisher is a true scientist and researcher. He has fully retired from his career position but can't stop working and seems to be spending his retirement working as a consultant. Just since 2023 he has been a co-author on four respected journals and penned a published opinion for Heath Physics. (Go to Google Scholar and search on 'Darrel R. Fisher'). His name has such clout that someone will likely have him peripherally involved in their research just so they can include him on as a co-author which is confirmation that someone as respected and knowledgable as him supports their work. Only the best of the best in a field get to the point that they churn out journal articles like this. Vivos having Fisher standing behind Radiogel and Isopet is a real asset.
At this year's IRPA he just presented a poster, but it does represent very recent results so it is valuable information (abstract below). As an aside he also taught a course on Sunday "Fundamental Principles of Medical Internal Radiation Dosimetry". In the description of the course they describe him as "Your instructor has more than 40 years of relevant experience in clinical radiopharmaceutical dosimetry and patient case studies, including 30 years as a member of the MIRD Committee of the Society of Nuclear Medicine and Molecular Imaging."
Abstract of poster he presented on Monday. I put in bold the items that largely put to rest my concerns in the recent X post. Dr. Fisher really doesn't care about Radiogel/Isopet what he cares about is radiation safety and clinical studies (as the google scholar search shows by how many technologies and areas he is involved). So again his stamp approval really matters as no one is going to believe he is a paid shill for a small biotech company.
Looking forward to seeing an end to the foolishness w the share price and this ridiculously low MC
yes, gonna take time, but I’ve been here 4 years and with things now coming to fruition the next 4 years of green are going to be much easier to ride
Or your triggered for selling into the last run lower than current low lol ....anyone trading around so called highs and lows currently good luck ...I've been here before in another otc and it went from 10 cents to dollars next day 🙃 enjoy the ride ...
Impatience will boomerang on this soon imo
Throw your technicals out the windows soon ...imo
I'm invested here since ADMD got out at split and back in after dust settled about 2017
Rum, I'm an investor of Vivos Inc which in someways is just a baby stock, the potential with humans is off the chart, it will take time to reach that potential. Traders are Gona trade; investors are Gona invest. The next domino is a big one! Good luck to the longs and all the investors.
You must be triggered and soft skinned
I have a friend who over the past 30 years just buys and holds solid companies such as Microsoft or basic QQQ… doesn’t try to trade around market peaks and dips, he’s up HUGE… some people here post things like, “I’m going to sell some here, then I’m going to sell more here, and if this happens I’m going to sell some there, etc” — The more I learn the more I am confident this medical tech is going to greatly reward long term holders, and those who sell larger portions along the way or try to trade around events (most retail are unsuccessful at that) are going to regret doing so… good luck to all
$RDGL
$RDGL Looks like profit taking could be over here after at couple of weeks..with the close above the 50 day MA thinking this pushes off it to test recent highs.. pic.twitter.com/7tGPLEOIXn
— Chris from Massachusetts AKA TommyboyTrader (@autumnsdad1) July 11, 2024
What previous estimates
Exactly BOB this company could see ....10x the previous plus it's just a baby currently
HONEY BEGGER unless you're a flipper 10 dollars to 20 per share previous is low within a few years
IMO approval is coming for human clinical trials with Mayo clinic and then approval for worldwide market...coming soon enough
This company and technology will have many facets to use this technology
The perverbial ICEBERG is melting and wow
ISOPET will also be huge imo the company will get the cost down to the masses
We have a Golden EGG being hatched
My previous estimates of value were intentionally conservative...this is HUGE
Great update from Vivos yesterday!
One of my biggest takeaways was the mention of two additional Mayo doctors, who are interested in using radiogel for lung cancer, attending the certification training.
Tells me Mayo has high level confidence in IDE approval and is already looking at additional treatment applications for radiogel.
Indeed
You can access the trades from this page by clicking on more then trades
Direct Interstitial Injection: An Approach to Optimizing Therapeutic Ratios for Safe and Effective Delivery of High-dose Radionuclide Therapy in Treating Solid Tumors (P446)
Mon, July 08
Gatlin C/D
Poster Session
Part of:
Poster Session 1
Info
Abstract Text:
The limiting constraint in all modes of radiation therapy is unwanted dose to non-target normal organs and tissues, which can cause severe side-effects. An ideal radionuclide therapy places 100% of the treatment dose uniformly within the clinical target volume without radionuclide out-migration from the tumor. Such treatment can be achieved by employing an optimum radionuclide and chemical form with carrier properties that facilitate injection, placement, and in-tumor retention. An optimized radiation dose achieves effective tumor destruction while preventing or minimizing normal tissue adverse reactions. Yttrium-90 emits no gamma rays and can be handled safely with negligible dose to workers, patients, and family members. Methods: Yttrium-90 was prepared as insoluble (yttrium phosphate) microparticles in a phosphate-buffered saline (PBS) solution mixed with a polymer composite (hydrogel) carrier for direct intra-tumoral injection. Privately owned cats, dogs, and horses presenting with soft-tissue sarcomas were treated at several veterinary clinics to demonstrate safety, best placement methods, and most effective treatment doses. Results: Upon injection using multiple parallel-needles, the carrier solution warmed and gelled in situ--forming a solid matrix that entrapped the Y-90 microparticles and prevented out-migration via blood circulation. Co-registered PET/CT imaging post-injection confirmed uniform placement in target tissues. Each subject exhibited an objective response to therapy; best results were associated with smaller tumors treated at higher doses (300 to 400 Gy). Treated animals experienced no radiation-related illness or adverse tissue reactions. Therapeutic ratios achieved ranged from 200:1 upwards to 10000:1. Complete tumor destruction was confirmed by histopathology. Conclusions: Some tumors represent poor candidates for surgical excision or cannot be treated using external beams for curative therapy. However, direct intra-tumoral injection of Y-90-microparticles in a polymer composite matrix provides a safe, efficient, high-dose therapy, with tumor cell killing associated with localized dose. Results of this research confirm the opportunity for multiple oncology applications in both human and veterinary patients.
Keywords:
radionuclide therapy cancer treatment yttrium-90
Session Topic:
MA5: Radiation Protection in Healthcare
Authors
Darrell R. Fisher, Ph.D.
Versant Medical Physics and Radiation Safety
Michael K. Korenko
Wow nice last minute of trading!
Its been tbe same bullshit for years
Last 5 serious buyers bought over ask. Tomorrow we will see big run.
Break out 0.20 by Tomorrow.!!!!
Not a coincidence what they're doing. Good catch! You're paying attention for sure.
Put them on ignore is my advice. Just s waste of time reading and posting to her
Ok, that must have happened well before 2018.
I wouldn’t call the late 2020 BDD submission a failure. It wasn’t exactly a total rejection, or close to that.
Based on the tweet today, looks like Darrel Fisher is at IRPA at the moment and expected to present.
Looking at the Convention Program, he will also be given an Achievement Award for outstanding contributions to the radiology space.
Go away and take your funky vibe with you while at it!
Never mind bantering with the wench for now
She has some excellent points now and then
And then other times not so much
Today's tweet was magnificent
Rejected submissions to the FDA. Those failures put RDGL on this path, and if successful (all signs point to success), welll worth it!!
RDGL Trade Data 07/10/2024
Date******Timestamp*Price*Volume
07/10/2024 15:59:54** 0.1896 5,000
07/10/2024 15:59:50** 0.18506 4,000
07/10/2024 15:59:49** 0.188 ***********88,893
07/10/2024 15:59:49** 0.19 ************41,000
07/10/2024 15:59:48** 0.1896 5,000
07/10/2024 15:59:47** 0.1896 5,000
07/10/2024 15:59:44** 0.19 **************10,000
07/10/2024 15:59:39** 0.1895 **********100,000
07/10/2024 15:59:36** 0.1895 1,107
07/10/2024 15:59:34** 0.1885 5,000
what failures of the past? ….
I have been in this stock for 6 years (since 2018), and I don’t remember any failures.
Anyone??? I clicked: "SHOW BOARD INTRO" button! How do I HIDE INTRO again??? I don't see the button!!
Looks like the shares Outstanding have increased by 48 million over the past year, YET during that dilution the share price has tripled which I find pretty IMPRESSIVE! So it seems RDGL is run by a shareholder friendly management team. And owned by a faithful diamond handed shareholder base who believe in the technology and it's potential. Wish I had found out about this company sooner.....maybe I've misread you after reading through many of your previous post here over the past year.....maybe I didn't.....it's the timing of some of your responses that I was calling into question.....
https://www.otcmarkets.com/stock/RDGL/security
As of August 4, 2023, there were 370,541,528 shares of the registrant’s common stock outstanding, 2,071,007 shares of the registrant’s Series
A Convertible Preferred Stock outstanding, 200,363 of the registrant’s Series B Convertible Preferred Stock outstanding and 385,302 of the
registrant’s Series C Convertible Preferred Stock outstanding.
As of May 3, 2023, there were 370,541,528 shares of the registrant’s common stock outstanding, 2,071,007 shares of the registrant’s Series A
Convertible Preferred Stock outstanding, 200,363 of the registrant’s Series B Convertible Preferred Stock outstanding and 385,302 of the
registrant’s Series C Convertible Preferred Stock outstanding
My wife said yrs. ago I was crazy for buying millions of shares of a penny stock like RDGL & I told her this bet could possibly pay off one day financially & humanely.
In addition, I reminded her that I always had large cajones* & didn’t mind taking a calculated risk— (marrying her for example or as a retail speculator) no guts-no glory in this life.
So far I have no regrets in going long on RDGL, ENZC & others, of course you can’t win them all as they say.
* Look at the one hung low pic & you can see they almost touch the ground.
GO RDGL ! I am blessed & always remember to follow your gut & heart. This ticker is cooking!!!
The failures of the past are 100% keeping this ticker from running. Hopefully, IDE is approved and we ride a rocket to the moon!!!
And if they get to treat Lung Cancer ….
Which it looks like they might.
Then this is a future $20 billion buyout from big pharma (at minimum).
And a future $200+ billion technology in value in the long term.
Judging by previos tests done with imaging of the Y90/gel, I think it's been shown there hasn't been any migration issues even before the gelation as that would show up even after gelation. I know you don't like the wording either way.
With that being said, I think FDA's concern was more long term migration due to body movements, pressure being applied, gravity, body functions and what not. Just a guess.
I think it’s absolutely ok to be a bit sceptic. That’s why many people in the market sell a bit of their shares at major runs and try to play with the house money, going into BIG NEWS. Nothing is ever guaranteed. As we are already seeing with the price action since submission vs what many have predicted. And some of those predictions had certainty behind them.
No one knows
This is not my first rodeo with radiogel submission to FDA. I had and held through my shares through the de nova and first IDE submission. In both cases investors felt approval was a slam dunk. Were you invested and go through both of those events? I think we have everything we can possible cover covered this go around. But how many times have we been jerked around in the past, so it is on my mind the FDA could do it again. Specific examples are the genotoxity testing (that no other brachytherapy product ever had to do) and extra rabbit tests. You have to admit the extra rabbits were a total moving of the bar that the FDA itself set.
I feel the problem with the FDA is it is full of civil servants with low pay making critical decisions and some of these FDA people have relationships with big companies that involve them getting a high paying job a few years down the road. The concern that government regulators make decisions that are influenced by future job prospects in related industries is legitimate and puts small companies at a disadvantage. Look at the fraud Boeing was recently charged with all the questions Boeings ability to police themselves (a gift handed to them by the FAA) raised in terms of why the FAA didn't do proper oversight of Boeing.
There is nothing investors or any small company can do about that. But it is on my mind.
Just think if you hadn't annoyed me with your post I would have not shared this more descriptive post of why I am anxious. I don't think the FDA can hold up radiogel from being approved forever. At some point they have to realize they have squeezed as much extra time before the approval as possible.
Now I expect to see a bunch of chicken little responses claiming I think my posts are going to make people sell. Maybe I won't maybe everyone who doesn't want to hear from me have me on ignore. No one should sell because of this IDE not being approved without any conditions or a little later. We are closer and the payoff will be huge.
Cheers!
speak for yourself, you are trying to manufacture worry, this is an approval wrap
a few times in the past few weeks I swear you come off like a closet SC8 fan, good grief
LET ME CORRECT MYSELF!!!!! EOD money buying was around $88,000 NOT HALF A MILLION....427,744 buys at the ASK during the last 4 1/2 minutes of trading was the BUY volume. If you include the sells in the last 5 minutes of trading. The last 5 minutes of trading was over half a million in volume. Not the money volume!
familyof5 Re: mikepgator post# 176871
Wednesday, July 10, 2024 4:30:24 PM
427,744 buys at the ASK during the last 4 1/2 minutes of trading. Over half a million dollars worth of BUY volume in less than 5 minutes.....pretty impressive Bullish close by any standard.
Can we break 19 cents tomorrow....and hold? Time will tell 🤞
I picked up about 300k shares, then I bidders jumping ahead of my order, and the volume really started coming in, I still had an open order at the close.
427,744 buys at the ASK during the last 4 1/2 minutes of trading. Over half a million dollars worth of BUY volume in less than 5 minutes.....pretty impressive Bullish close by any standard.
I think we can break new highs this week
Would explain the over thinking all of the time
Considering today's and yesterday's trading activity and new revelation. I'd say the rest of the week should be solid GREEN.....
I think he is a she actually
Nah not when your hiding out in the wide open sir.....
Yep, I'm not proud of it, but common phrase I have heard going through life is "Ya know you don't have to say everything that you think." Those are wise words indeed, and I have improved on holding some things back. But I still say (and post) what others think I should have just kept to myself more than I should. Who knows maybe someday I will stop, but I'm pretty old so the best I can do is try to minimize it. Anyone who can't bear it should ignore me.
Get used to it, he does this all of the time on everything the company posts.
He worries he puts that on here on iHub,
Every once in awhile he has a good point other than that.
After that presentation it will be published most likely 👍🏻👍🏻
The company is engaging the FDA for permission to use RadioGel™ for the treatment of advanced basal and squamous cell skin cancers. The RadioGel™ Veterinary Solutions division of Vivos is focused on demonstrating the safety and therapeutic effectiveness for different animal cancers in four different university veterinary hospitals. Vivos is positioning itself so that after this demonstration phase, The Company can begin to generate revenues through the sale of RadioGel™ to private animal clinics.
The Company currently is outsourcing material aspects of manufacturing of its product in the United States and intends to enter into licensing arrangements outside of the United States for the manufacturing and distribution of RadioGel™ in other countries.
RadioGel™ also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to 6 weeks or more to deliver a full course of radiation therapy. This is an outpatient treatment much safer to the personnel treating the patient than competing brands and the patient can go home immediately with no risk to family members.
What are the advantages of RadioGel™?
Based upon its studies and analyses, or general application of experience with current brachytherapy devices and Yttrium-90, Vivos believes that its brachytherapy products are likely to offer the following benefits, among others, for patients and medical professionals:
•Maximizing Therapeutic Index: The short-range beta particles emitted by Y-90 deliver radiation energy within a tight range. This enables radiation to be selectively delivered to target tissues while minimizing radiation dose to nearby normal tissues. High therapeutic indices imply that more radiation energy may be imparted to target tissues, with less radiation reaching adjacent normal tissues.
•Half-Life: Y-90 has a half-life of just 2.7 days. Many traditional brachytherapy products use isotopes with longer half-lives such as 9.7 days for cesium-131, and sixty days for iodine-125.
•Optimized Delivery Method: Current brachytherapy devices place permanent metal seeds in the prostate by using up to 30 large needles. By contrast, Vivos’s Y-90 RadioGel™ device is designed to be administered in a minimally invasive procedure with small-gauge needles.
•No Permanent Seeds Remaining: Current brachytherapy devices place permanent metal seeds in the tumor. Vivos’s Y-90 RadioGel™ device utilizes a biodegradable, non-toxic polymer that is ultimately absorbed by the body. This eliminates the possibility of a long-term seed migration or other problems that may sometimes arise when seeds remain in the body.
•Good Safety Profile: Many traditional brachytherapy devices utilize isotopes that emit x-rays (akin to gamma radiation). X-rays or gamma radiation travels within and outside of the body and have long half-lives. Vivos’s brachytherapy products use the Yttrium-90 isotope, which is a beta-emitter. Yttrium-90 beta-emissions travel only a short distance and have a short half-life of 2.7 days.
•Potential Lower Cost: Yttrium-90 supplies are readily accessible and are relatively inexpensive. The elimination of the metal or glass enclosures used in traditional brachytherapy seeds greatly reduces manufacturing costs.
What is the market for RadioGel™?
Reliable sources estimate that annual sales of brachytherapy products exceed $2 billion, about half of which are in the United States. The size of the U.S. brachytherapy market for prostate cancer brachytherapy is somewhere between $90 million and $130 million per year. The market for liver and breast cancer combined is comparable.
What is Brachytherapy?
Brachytherapy is the use of radiation to destroy cancerous tumors by placing a radiation source inside or next to the treatment area. According to Global Industry Analysts, by 2016 the U.S. brachytherapy market will reach $2 billion. It is estimated that the U.S. market represents approximately half of the global market. Vivos believes there are significant opportunities in prostate, breast, liver, pancreatic, head and neck cancers. The 2013 U.S. estimated new cases according to the American Cancer Society are 240,000 prostate cancer, 235,000 breast cancer, and 31,000 liver cancer.
Are there other markets for RadioGel™?
March 15th, 2016, Vivos Inc. announced the formation of a new, wholly-owned subsidiary, IsoPet Solutions Corporation, to focus on the vibrant and expanding veterinary oncology market. In August 2017 the subsidiary was changed and made into a separate operating division inside the Company.
The IsoPet™ Veterinary Solutions division will focus on bringing RadioGel™ yttrium-90 brachytherapy products to veterinary oncologists to treat dogs and cats suffering from tumor cancers.
There are over 150 million pet dogs and cats, with over 1/3 of the households in the US owning at least one dog, and just under 1/3 owning at least one cat. IsoPet Solutions is establishing the infrastructure necessary to provide product to veterinary clinics including regulatory clearances and compliance. The division will also provide product awareness and education to veterinary oncologists. Initial treatments are to be coordinated through the Chair of the Company’s Veterinary Medicine Advisory Board, Dr. Alice Villalobos.
CEO and President Dr. Mike Korenko stated: “IsoPet Solutions allows specific resources to focus on the use of our RadioGel™ Yttrium-90 brachytherapy products in the veterinary space. We believe that RadioGel™ is positioned to build a significant presence in the cancer treatment tool-kit of veterinary oncologists.”
Dr. Alice stated: "I am quite excited at the opportunity to work with RadioGel's™ team to integrate their products into the cancer treatments of companion animals. Cancer affects 50% of dogs over age ten and one in four dogs under age ten. For many years, we have been searching for a useable and effective agent such as RadioGel™ Y-90 brachytherapy devices that can be delivered into tumors on an outpatient basis. I believe that veterinary oncologists around the globe will finally have an ideal product line for the treatment of accessible and inoperable tumors."
What are the steps for FDA clearance?
Vivos met at the FDA offices to discuss next steps, expectations and required testing to progress towards obtaining marketing clearance for the Y-90 RadioGel™ device. The FDA and Vivos management and consulting team are working closely in order to obtain all appropriate data and benchmarks the FDA requires in order to proceed with providing final clearance for marketing the device in the United States.
August 2016, Vivos announced a partnership with IsoTherapeutics Group, a third-party radiopharmaceutical R&D company, to provide commercialization support and conduct additional studies as requested by the FDA for the Y-90 RadioGel™ device. IsoTherapeutics has completed the first stage of the project, comprised of tech transfer, manufacturing and in vitro testing. The next stage, comprised of additional in vitro and in vivo testing. Upon completion of these studies, Vivos anticipates submittal (direct De Novo) for FDA clearance for full commercialization in the U.S. (see company press releases for continual updates on this evolving process).
Press Releases 2018 ( Change in Company name and trading symbol • Jan 2, 2018)
Jan 2, 2018, Advanced Medical Isotope Corporation (ADMD) Announces Corporate Name Change to Vivos Inc., and Ticker Symbol Change to RDGL
Press Releases 2017 ( Change in Management & Directors Dec 2016)
Dec 20, 2016, AMIC's Board of Directors Appoints Dr. Michael Korneko CEO and Dr. Carlton Cadwell Chairman of AMIC
Jan 11, 2017, AMIC's New CEO Issues Letter to Shareholders
Feb 14, 2017, AMIC's CEO Releases Shareholder Letter Outlining New Streamlined Path to FDA Submission
Feb 28, 2017, AMIC's New CEO Releases Shareholder Letter Announcing and Discussing their Cancer Indication Selection to pursue FDA Approval
Mar 7, 2017, AMIC's New CEO Releases Shareholder Letter Detailing Launch of Veterinary Oncology Division with Radiogel
Mar 23, 2017, Update on Feline Cancer Treatment and Improvement to Financial Structure
Jul 6, 2017, AMI Requests Pre-Submission Meeting with FDA
Jul 11, 2017, ADMD Makes Significant Improvement to its RadioGel™ Brachytherapy Product
Jul 27, 2017, ADMD to Host Shareholder Update Webcast with Live Q&A
Aug 2, 2017, Advanced Medical Isotope Corp. Announces Results of Shareholder Meeting, Welcomes Two New Members of the Board of Directors
Sep 14, 2017, Advanced Medical Isotope Corporation has its first discussions with private animal consortiums to utilize RadioGel™
Independent Analyst Research and Price Target
Presentation(s) from CEO & President, Dr. Mike Korenko.
2017 - LINK HERE
STOCK SYMBOL: OTC: RDGL
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |